Atea Pharmaceuticals (AVIR) Earnings Date, Estimates & Call Transcripts $2.82 -0.12 (-4.08%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$2.82 +0.01 (+0.18%) As of 04/15/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Atea Pharmaceuticals Earnings Summary Upcoming Earnings DateMay. 13After Market ClosesEstimatedConsensus EPS (Mar. 6) -$0.35 Actual EPS (Mar. 6) -$0.40 Missed By -$0.05 Atea Pharmaceuticals issued Q4 2024 earnings on March 6, 2025, reporting an EPS of -$0.40, which missed analysts' consensus estimates of -$0.35 by $0.05. With a trailing EPS of -$2.00, Atea Pharmaceuticals' earnings are expected to grow next year, from ($2.01) to ($1.79) per share. Q4 2024 Earnings ResourcesQ4 2024 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Slide Deck Annual Report (10-K)AVIR Upcoming EarningsAtea Pharmaceuticals' Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q1 2025 Earnings ReportSlide DeckFull Screen Slide DeckPowered by Get Atea Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atea Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataAVIR Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Remove Ads Atea Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.48-$0.48-$0.48Q2 20251-$0.48-$0.48-$0.48Q3 20251-$0.49-$0.49-$0.49Q4 20251-$0.48-$0.48-$0.48FY 20254-$1.93-$1.93-$1.93Q1 20261-$0.40-$0.40-$0.40Q2 20261-$0.40-$0.40-$0.40Q3 20261-$0.40-$0.40-$0.40Q4 20261-$0.39-$0.39-$0.39FY 20264($1.59)($1.59)($1.59) Remove Ads Atea Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/13/2025(Estimated)-------3/6/2025Q4 2024-$0.35-$0.40 -$0.05-$0.40--11/7/2024Q3 2024-$0.50-$0.37+$0.13-$0.37--8/7/2024Q2 2024-$0.76-$0.48+$0.28-$0.48--5/14/2024Q1 2024-$0.61-$0.75 -$0.14-$0.75--2/28/2024Q4 2023-$0.44-$0.47 -$0.03-$0.47--11/8/2023Q3 2023-$0.46-$0.40+$0.06-$0.40--8/8/2023Q2 2023-$0.47-$0.34+$0.13-$0.34--5/8/2023Q1 2023-$0.51-$0.43+$0.08-$0.43-- Atea Pharmaceuticals Earnings - Frequently Asked Questions When is Atea Pharmaceuticals's earnings date? Atea Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 13th, 2025 based off last year's report dates. Learn more on AVIR's earnings history. Did Atea Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Atea Pharmaceuticals (NASDAQ:AVIR) missed the analysts' consensus estimate of ($0.35) by $0.05 with a reported earnings per share (EPS) of ($0.40). Learn more on analysts' earnings estimate vs. AVIR's actual earnings. How can I listen to Atea Pharmaceuticals's earnings conference call? The conference call for Atea Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How can I read Atea Pharmaceuticals's conference call transcript? The conference call transcript for Atea Pharmaceuticals's latest earnings report can be read online. Read Transcript How much profit does Atea Pharmaceuticals generate each year? Atea Pharmaceuticals (NASDAQ:AVIR) has a recorded net income of -$135.96 million. AVIR has generated -$2.00 earnings per share over the last four quarters. What is Atea Pharmaceuticals's EPS forecast for next year? Atea Pharmaceuticals's earnings are expected to grow from ($2.01) per share to ($1.79) per share in the next year. More Earnings Resources from MarketBeat Related Companies Syndax Pharmaceuticals Earnings Date Wave Life Sciences Earnings Date Collegium Pharmaceutical Earnings Date Enliven Therapeutics Earnings Date Dyne Therapeutics Earnings Date Structure Therapeutics Earnings Date 89bio Earnings Date Chimerix Earnings Date Avid Bioservices Earnings Date Arcus Biosciences Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside? Remove Ads This page (NASDAQ:AVIR) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AVIR Stock Free AVIR Stock Alerts